Ashley E. Ross, MD, PhD, presented “Considerations for the Clinical Impact of Next Generation Imaging in Prostate Cancer” during The 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 3, 2019 in Boston, Massachusetts.
How to cite: Ross, Ashley E. “Considerations for the Clinical Impact of Next Generation Imaging in Prostate Cancer” October 3, 2019. Accessed Dec 2024. https://dev.grandroundsinurology.com/considerations-for-the-clinical-impact-of-next-generation-imaging-in-prostate-cancer/
Considerations for the Clinical Impact of Next Generation Imaging in Prostate Cancer – Summary:
Ashley E. Ross, MD, PhD, Executive Medical Director of the Mary Crowley Cancer Research Center in Dallas, discusses the current and potential impact of PSMA PET imaging on the identification and treatment of localized prostate cancer. He notes how PET PSMA and fluciclovine imaging can increase the accuracy of detecting clinically significant localized disease. Dr. Ross further discusses how PET imaging assists in risk stratification of candidates for treatment of HSPC, nmCRPC using salvage local therapy, metastasis-directed therapy, or intensification of systemic therapy. He also discusses how PET imaging can help identify candidates for cure with local treatments.
About The 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer:
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a multi-day, multi-disciplinary forum designated to informing health care stakeholders about topics including in-vitro fluid- and tissue-based molecular diagnostics, novel observation strategies such as active surveillance, and novel therapeutic interventions. Along with this forum’s efforts to form a consensus on the future of prostate diagnostics and precision care, it aims to create an educational and research strategy for its realization. Dr. Ross presented this lecture during the 4th iteration of this Summit in 2019.
ABOUT THE AUTHOR
Ashley E. Ross, MD, PhD, is Executive Medical Director at Mary Crowley Cancer Research in Dallas, Texas. He also practices as a physician with Texas Oncology Practice Associates and Texas Urology Specialists. He was formerly an Associate Professor of Urology and Oncology at the Johns Hopkins School of Medicine where he led the Brady Urological Prostate Cancer Program and co-directed the Sidney Kimmel Cancer Center’s multidisciplinary prostate cancer clinic. Dr. Ross has been particularly interested in evaluating novel diagnostics and therapeutics and has led trials testing biomarkers for prostate cancer diagnosis, novel imaging modalities for staging, genomic markers to assess risk, and therapeutic trials for high-risk disease and low-volume metastatic disease. Dr. Ross is an Associate Editor of the “Journal of Prostate Cancer and Prostatic Diseases,” “Urology,” and “Annals of Surgical Oncology.” He is on the editorial board of the “British Journal of Urology” and “Urology Practice.” He has been recognized with numerous awards and honors, including the Johns Hopkins Clinical Scientist Award, the Department of Defense Prostate Cancer PTRA Award, the Patrick C. Walsh Prostate Cancer Research Award, and a Prostate Cancer Foundation Young Investigator Award.
